Nautilus Biotechnology, Inc. NAUT
Super Investor & Insider
1
Fondi che lo detengono
#1520
Rank consenso
1.4%
% dei portafogli
$156,539
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Polen Capital Management · Polen Capital Management | 0% | Buy | 40,345 | $156,539 |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Nautilus Biotechnology, Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. Its core offering, the Nautilus Platform, provides an end-to-end proteomics solution that includes instruments, consumables, and software for analy…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees127
TickerNAUT
Statistics
Market Cap$280.2M
Revenue (TTM)$0
Net Income-$59.0M
Net Margin—
EPS$-0.47
P/E-4.95
P/S—
P/B1.99
EV/EBITDA-3.71
ROE-33.7%
Dividend Yield—
Price$2.21
Data: Twelve Data · Revenue = mcap / P/S